Month: December 2025

SHENZHEN, Dec 11, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms.Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals.The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients.More Information about Y-3 for InjectionThe pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects.The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent.About StrokeAccording to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2025年12月11日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司（"康哲药业"）欣然宣布，1类新药注射用Y-3（拟定中文通用名：注射用洛贝米柳）（"注射用Y-3"或"产品"）新药上市许可申请（NDA）已于2025年12月11日获得中国国家药品监督管理局（NMPA）受理。产品为一种拟用于急性缺血性卒中的脑细胞保护剂。注射用Y-3靶点明确，作用机制清晰，可发挥多重疗效。注射用Y-3作为全球首个基于脑卒中病理过程重要靶点PSD95-nNOS和MPO开发的脑细胞保护剂，作用于缺血性脑卒中缺血级联反应多个关键病理过程，通过多靶点高选择性协同，更有利于发挥脑细胞保护作用。产品具有优异的治疗缺血性脑卒中和潜在的预防卒中后抑郁焦虑症状的作用。注射用Y-3临床数据优异，疗效优异，安全性佳。产品中国II期临床试验研究结果表明，在发病48小时内的缺血性脑卒中患者中，使用Y-3 40mg 每日一次治疗后，达到90天优良功能结局（mRS评分0～1分）的患者比例较安慰剂组显著提高，率差达到16%。产品中国Ⅲ期临床研究由首都医科大学附属北京天坛医院任组长单位，于全国近40家研究中心纳入发病时间≤48小时的急性缺血性脑卒中患者近1,000例，旨在评价注射用Y-3治疗发病在48小时以内的急性缺血性脑卒中患者的有效性和安全性。Ⅲ期临床研究达到主要疗效终点，患者临床获益明显，整体安全性良好。主要研究结果未来计划在国际学术会议上公布，整体研究将在国际学术期刊上发表。中枢神经系统（CNS）是康哲药业的核心优势领域之一，已逐步形成深度布局。产品组合包括在售创新药维图可（地西泮鼻喷雾剂）、原研品牌药黛力新（氟哌噻吨美利曲辛片）以及处于NDA审评中的改良型新药ZUNVEYL（葡萄糖酸苯加兰他敏肠溶片），已夯实市场基础。注射用Y-3的加入，将进一步强化产品矩阵，在专家网络与市场资源上产生高效协同。期待注射用Y-3早日上市，为中国缺血性脑卒中患者带来疗效优异、作用更全面的新一代脑细胞保护剂，并凭借集团卓越的商业化经验与合规高效的运营体系，加速推动创新疗法惠及更多患者。关于注射用Y-3的更多信息急性缺血性脑卒中的病理过程高度复杂且相互关联，临床亟需多靶点多机制协同干预，以实现对复杂的缺血级联反应的更有效调控，从而提高治疗效果和患者生活质量。注射用Y-3可解离PSD95-nNOS耦联，抑制MPO活性，还可增强α2-GABAA受体（一种具有抗抑郁、抗焦虑功能的GABAA受体亚型）活性，通过这种多靶点高选择性协同机制，有望实现"卒中治疗与卒中后抑郁焦虑预防"同步干预的技术突破，使注射用Y-3有望成为一种疗效优异，作用更全面的新型脑细胞保护剂。于2024年第十届欧洲卒中组织会议（ESOC 2024）上以口头壁报形式发表的注射用Y-3治疗急性缺血性卒中的II期临床试验研究结果表明，在发病48小时内的缺血性脑卒中患者中，使用Y-3（20mg、40mg、60mg，每日一次）治疗后达到90天优良功能结局（mRS评分0～1分）的患者比例显著高于安慰剂组（20mg: 67.8% vs 60.7%、40mg: 76.7% vs 60.7%、60mg: 70.0% vs 60.7%）。且产品在急性缺血性脑卒中人群的安全性与安慰剂相当，表现出良好的耐受性。于2023年8月24日，康哲药业通过其全资附属公司与一家以临床需求为导向、创新与研发驱动的新药企业南京宁丹新药技术股份有限公司就产品签署合作协议（"协议"）。根据协议，康哲药业获得产品在中国大陆、香港特别行政区、澳门特别行政区的独家推广权。协议期限为永久。关于脑卒中根据国家卫健委发布的《脑血管病防治指南（2024年版）》，我国每年新发卒中约394万例，占全球新发病例三分之一，其中缺血性卒中占比约72%，年新发病例超280万；现患病的卒中患者已超2,800万人[1]。2021年中国死因监测数据显示，卒中死亡占全国总死亡人数的23%[1]。过去三十年，我国卒中相关残疾的疾病负担持续加重，叠加人口老龄化加快等因素，未来卒中防控压力将进一步增大，给患者家庭和社会带来巨大挑战[1]。此外，卒中后抑郁和焦虑是卒中常见并发症，发病率分别达到约30%和25%[2]，会影响患者神经功能恢复，甚至增加死亡风险，严重影响患者预后。注射用Y-3对广大卒中患者长期神经功能改善和总体预后具有重大潜在价值，市场前景广阔。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1.中华人民共和国国家卫生健康委员会. 脑血管病防治指南（2024年版）[J]. 磁共振成像, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.2.陈杏雨, 吕小涵, 李瑞娜, 等. 卒中后焦虑[J]. 国际脑血管病杂志, 2022, 30(2) : 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

5N+ Purity and On-Spec EBC Confirm Lac Knife's Potential as a North American Source of Ultra-High-Performance Graphite ApplicationsOttawa, Ontario--(ACN Newswire via SeaPRwire.com - December 11, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and innovator of next-generation battery technology, is pleased to announce that follow-on purification and elemental analysis of material from its Lac Knife deposit (concentrate Lot ID: GN25073005) achieved 99.9996 wt.% ("5N+") and an Equivalent Boron Concentration ("EBC") of 2.03 ppm, confirming the material is within nuclear-grade specification and meets the technical thresholds required for several high-value advanced materials markets.The test work, conducted using electrothermal purification with no halogen gases (e.g. chlorine) or acids, produced this ultra-pure result in two (2) hours, further validating a chemical-free, environmentally advantageous pathway compared to conventional purification methods. These results directly support Focus's ongoing engineering and scale-up programs funded under Natural Resources Canada's ("NRCan") Global Partnerships Initiative ("GPI"), under which the Company was awarded a non-repayable contribution of up to $14.1 million to accelerate North American capacity for clean, advanced material processing.Subsequent elemental analysis calculated in accordance with ASTM C1233-15: Standard Practice for Determining Equivalent Boron Contents of Nuclear Materials yielded an Equivalent Boron Concentration ("EBC") of 2.03 ppm (Table 1), which falls below the critical 3 ppm threshold often cited for nuclear-grade graphite applications. The calculated EBC value is the most critical test of purity for nuclear industry use.These results suggest that Lac Knife graphite has the potential to serve markets requiring ultra-high-purity large and jumbo flake natural graphite. Achieving both 5N+ purity and a high proportion of large-flake concentrate is uncommon in the natural graphite industry and may provide Focus with opportunities in markets historically reliant on synthetic graphite or otherwise inaccessible to peers. These findings are consistent with peer-reviewed research published in ACS Omega ("Ultrahigh Temperature Purification of Graphite for the Development of a Continuous Process," ACS Omega, 2025), conducted by American Energy Technologies Company ("AETC") and NRCan, which demonstrated that ultrahigh-temperature purification of natural Canadian graphite can produce materials exhibiting purity and crystallinity suitable for advanced applications. Focus's ongoing testwork indicates that residual impurities appear primarily on the surface of the graphite flake—as evidenced by ultra-fine features observed through scanning electron microscopy—suggesting that purification efficiency is strongly influenced by surface cleaning dynamics rather than structural defects within the carbon lattice.Dean Hanisch, Chief Executive Officer of Focus commented, "These results validate Lac Knife as one of the rare unique natural graphite deposits capable of competing in high margin advanced technological markets and as a potential alternative to synthetic materials that are more expensive and have a larger environmental impact. With support from Canada's Federal Government, through Natural Resources Canada's Global Partnerships Initiative, we are now positioned to accelerate our scale-up work and unlock commercial pathways across nuclear energy, defense systems, graphene production, and next-generation electronics."Lac Knife graphite's combination of ultra-high purity and large flake distribution positions it for a range of advanced industrial, clean energy, and high-technology applications.Unlocking Advanced Markets Beyond NuclearBeyond nuclear applications, the ultra-high purity and medium-grain morphology of Lac Knife graphite position the material as a strategic feedstock for several advanced technology markets facing supply shortages, performance bottlenecks, and increasing scrutiny over material purity.Graphene & Few-Layer Graphene (FLG) ProductionIn the graphene sector, precursor quality is the primary determinant of performance. Impurities commonly found in natural graphite—typically 0.5-1 microns in size, or roughly one thousand (1000) times thicker than a graphene layer—are known to disrupt electrical, thermal, and mechanical properties unless fully removed. Lac Knife's 5N+ purity eliminates these defects at the source, allowing the flake to exfoliate cleanly into high-value graphene structures.Peer-reviewed research published in Carbon ("Influence of graphite geography on the yield of mechanically exfoliated few-layer graphene," Carbon, 2023) demonstrates the significance of geological origin in FLG production. In follow-on AETC—Yale University testing based on the methodologies outlined in that study, Lac Knife graphite achieved a record-high few-layer graphene yield of 22% ± 3%, outperforming all other natural samples evaluated and showing exfoliation behavior that synthetic graphite could not replicate.Taken together, these results position Lac Knife as one of the few North American natural flake sources capable of supplying advanced graphene markets, including conductive coatings, EMI-shielding materials, flexible electronics, sensors, and next-generation energy storage systems.Defence: IR Obscuration & Countermeasure SystemsThe defence sector presents another major opportunity. Modern warfare increasingly requires materials capable of obscuring both visible and infrared signatures. Traditional obscurants—such as bronze flakes, titanium dioxide, and red phosphorus—pose toxicity, safety, and performance challenges. High-purity graphite and graphene derived from Lac Knife offer a lightweight, non-toxic, and thermally stable alternative capable of generating rapid-dispersion and longer-lasting obscurant clouds.These materials are applicable to 40 mm muzzle-blast cartridges, airburst obscuration rounds for UAVs and rotorcraft, countermeasure dispenser systems, and naval surface-ship defence platforms. The U.S. Department of War currently procures graphene-based obscurants at approximately US$30,000 per ton, reflecting both strategic importance and limited supply. Lac Knife's purity is essential here, as impurities directly interfere with graphene formation and degrade obscurant performance.Stealth Coatings & Electromagnetic Protection SystemsUltra-high purity graphite also plays a critical role in stealth coatings and electromagnetic protection systems. Engineered systems operating across the 400 MHz to 30 GHz spectrum require materials that deliver highly reproducible electrical conductivity, thermal stability, and particle uniformity.These coatings and composites are used in radar-absorbing structures for stealth UAVs, thermal-vision targeting systems, and a range of low-observable technologies. Because deviations in graphite purity can compromise system reliability or operator safety, defence and shielding markets pay substantial premiums—often up to US$50,000 per ton—for 5N-grade material. Lac Knife's combination of purity, consistency, and grain structure aligns closely with these stringent requirements and allows for further refinement into fine, superfine, ultrafine, or microfine grades without compromising integrity.Critical Infrastructure Hardening (HEMP, IEMI and Geomagnetic Storms)The same purity advantages extend into critical infrastructure protection. As governments and utilities work to harden electrical grids, substations, and 5G networks against high-altitude electromagnetic pulses (HEMP), intentional electromagnetic interference (IEMI), and severe geomagnetic storms, materials must perform reliably across high-frequency ranges and under extreme operating conditions.Graphite-based shielding and coatings designed for these systems rely on predictable, reproducible material behavior—standards that only ultra-high purity graphite can meet. Lac Knife's 5N+ output offers the reliability required for these mission-critical applications.Additional High-Value Markets Enabled by 5N+ PurityIn addition to these strategic sectors, Lac Knife's purity profile and particle characteristics also unlock potential in several high-value industries, including thermal management components for semiconductors and LEDs, high-pressure synthetic diamond production, PEM and SOFC fuel-cell bipolar plates, and laboratory-grade graphite consumables where contamination must be tightly controlled. In each of these markets, ultra-high purity reduces defects, increases stability, and improves overall system performance, enabling natural graphite to compete directly with synthetic alternatives.Next Steps in Technical ValidationFocus is advancing a comprehensive technical qualification program to further define Lac Knife's suitability for nuclear and advanced material markets. Ongoing nuclear graphite testing includes detailed characterization of particle size distribution, compressibility, electrical resistivity, and coefficient of friction—parameters that determine whether a graphite material can perform reliably under the thermal, mechanical, and irradiation stresses present in high-temperature reactor environments. The Company expects to fabricate and evaluate near-net-shape graphite bricks, an essential step toward assessing Lac Knife material in full-scale core component geometries and within ASME Division 5 design criteria.In parallel, Focus is extending its validation program—supported through NRCan's Global Partnerships Initiative ("GPI")—advanced materials markets. Current work programs under consideration include assessing Lac Knife graphite as a precursor for high-yield graphene, nano-wafer substrates, thin-film semiconductors, next-generation electronic components, and aerospace composites, including unmanned aerial systems (UAS). These sectors demand highly reproducible, ultra-high-purity carbon materials traditionally sourced from synthetic graphite. Early results indicate that Lac Knife's 5N+ natural graphite may offer a technically competitive—and potentially more sustainable—North American alternative to synthetic feedstocks across multiple high-value applications.ElementImpurity Limit (mg/kg)EBC FactorEBC CalculationAg0.050.00830.000415Al10.00010.0001B0.1210.12Ca0.360.00020.000072Cd50.31721.586Cl1.50.01340.0201Co0.050.00890.00445Cr0.120.00080.000096Cu0.250.00080.0002Dy0.050.08180.00409Eu0.10.4250.0425Fe0.210.00060.000126Gd0.054.39910.219955K0.60.00080.00048Li0.030.14390.004317Mn0.120.00340.000408Mo0.150.00040.00006Na0.0850.00030.0000255Ni0.180.00110.00198S1.40.00020.00028Si1.460.00010.000146Sm0.050.53360.02668Th0.010.00050.000005Ti0.530.00180.000954U0.050.00050.000025V0.080.00140.000112 Total 2.0277895 Table 1: EBC Calculation, Thermally Purified Lac Knife Lot ID: GN250730005Figure 1: Particle Size Distribution, Thermally Purified Lac Knife Lot ID: GN250730005To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/277711_279dc9a07490cbe0_001full.jpgTap DensityScott VolumeSurface AreaLOI g/ccg/ccm2 /gWt. % C0.60.41.499.9996 Table 2: Data, Thermally Purified Lac Knife Lot ID: GN250730005% TileSize (um)D10105.2D50337.3D90673.8MV368.5 Table 3: Data (2), Thermally Purified Lac Knife Lot ID: GN250730005Qualified PersonDr. Joseph Doninger, Director of Technology and Manufacturing for Focus Graphite, is the Qualified Person ("QP") as defined under National Instrument 43-101 - Standards of Disclosure for Mineral Projects. Dr. Doninger has reviewed and approved the technical information contained in this news release. Dr. Doninger is a chemical engineer and the developer or co-developer of multiple U.S., European, and Canadian patents relating to carbon processing technologies and purification equipment. He has authored or co-authored more than two dozen technical papers and studies on graphite composite anodes, carbon-based materials for electrochemical energy storage systems, and advanced graphite for lithium-ion batteries.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.com.LinkedIn: https://www.linkedin.com/company/focus-graphite/ X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated performance and downstream applicability of ultra-high-purity graphite derived from the Lac Knife project; the potential for 5N+ purification results and nuclear-grade Equivalent Boron Concentration ("EBC") values to be replicated at larger scale; the implications of testwork conducted under Natural Resources Canada's Global Partnerships Initiative ("GPI") and the expected outcomes of related engineering, scale-up, and validation programs; the ability of Lac Knife graphite to meet nuclear, graphene, defense, electromagnetic shielding, thermal management, semiconductor, and other advanced material specifications; the potential commercial pathways associated with supplying high-purity natural graphite as an alternative to synthetic graphite; and the Company's strategy to position itself within North American supply chains for clean energy, advanced manufacturing, aerospace, and critical infrastructure markets.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277711 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年12月11日 - (亚太商讯 via SeaPRwire.com) - 工业供应链数智化领航者京东工业（7618.HK）近期完成招股，预期于12月11日登陆港交所，成为京东生态旗下第 6 家上市公司，开启对接全球资本的新征程。暗盘阶段，公司股价波动不大较为稳定，不过笔者认为，暗盘作为新股上市前的「预演场」，其价格受制于有限的流动性、短期情绪及部分套利资金行为，往往不能完全反映一家公司的内在价值与长期潜力。对于京东工业这样一家扎根于中国庞大工业腹地、已构建起深厚护城河的产业领导者而言，短暂的暗盘「微震」，或许正是投资者摒弃噪音、聚焦其核心价值的绝佳时机。行业龙头地位稳固 万亿赛道红利尽显当前，中国工业供应链正处在数字化转型的关键拐点。据灼识咨询预测，2024年中国工业供应链技术与服务市场规模为 0.7万亿元，预计到2029年达到 1.1 万亿元，2024-2029 年复合增长率高达9.8%。随着工业企业降本增效需求的日益迫切，中国工业供应链市场数字化渗透率仍有巨大提升空间。在这一蓝海市场，京东工业早已占据行业金字塔尖的核心位置，无疑将成为这一趋势的最大受益者。其通过「太璞」这一「数」、「实」结合的全链路数智化工业供应链解决方案，推动工业供应链的数字化转型，助力客户实现保供、降本、增效及合规。按 2024 年交易额计算，公司稳居中国工业供应链技术与服务市场榜首。在竞争更为激烈的 MRO 采购服务领域，其龙头地位同样无可撼动，2024年交易额为第二名的近三倍。在高度分散、传统冗长的工业供应链领域，这一市场份额和领先优势的建立，本身就证明了其模式的有效性和强大的客户认可度。供给端，截至2025年上半年底，京东工业已整合 15.8 万家供货商，构建起覆盖 80 个产品类别的超 8110 万 SKU 庞大供给体系。客户端，截至2025年6月底的过去12个月，京东工业服务着约 1.11 万重点企业客户，更囊括了 60% 的中国 《财富》 500 强和 40% 的在华全球《财富》500 强企业，广泛的客户基础构筑了稳定的增长基本盘。数智化三重壁垒 打造稳固竞争优势如果说行业地位是京东工业的「硬名片」，那么数智化供应链体系就是其最深的「护城河」。京东工业的「太璞」解决方案，深入客户采购战略规划、供货商管理、履约运营乃至合规管控等各个环节。它不仅提供商品，更提供采购咨询、交易平台服务、广告服务等技术与服务。这种深度赋能，使其从赚取商品差价的「贸易商」，转型为说明客户优化整体供应链效率、节省综合成本的「合作伙伴」，商业模式的层次和利润空间更为丰厚。轻资产运营模式更让公司实现了规模与利润的双赢。通过数智化连结终端需求与供应端产能，部分订单直接由供货商发货，既整合了第三方履约能力，又减少了物流资产投入。这一模式推动公司盈利快速改善，从 2022 年的经调整净利润约 7.1亿元，到 2023 年8.2亿元，再到2024 年增长至 9.1亿元，2025 年上半年经调整净利润同比再增 34%，达到5.0亿元，经调整净利率同比增加0.5个百分点，盈利能力持续提升。与此同时，京东工业正以技术与业务双轮驱动拓展增长边界，在技术端，持续迭代工业大模型应用，深度赋能商品治理、需求预测等关键环节，进一步强化端到端智能解决方案能力；在国际业务方面，依托现有资源优势，积极拓展海外市场，复制国内成熟数智化供应链模式，对接全球工业资源构建跨境服务网络，挖掘万亿级跨境工业供应链服务潜力。从行业发展趋势来看，工业供应链的数字化、智慧化是不可逆转的潮流。京东工业在万亿赛道的龙头地位、数智化构建的核心壁垒、持续改善的盈利质量，以及背后中国工业供应链转型升级的时代红利，共同构成了其长期投资价值的坚实基础。随着公司上市后业务的持续推进与价值的逐步兑现，市场终将重新认知这家工业供应链巨头的成长潜力。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年12月11日 - (亚太商讯 via SeaPRwire.com) - 香港电子商务领域代表企业贸易通电子贸易有限公司（"贸易通"）与香港数字银行、腾讯控股有限公司控股企业富融银行有限公司（"Fusion Bank"）今日宣布签署合作备忘录，携手推动中小企数码融资、跨境贸易便利化及金融科技创新，助力本地企业把握数码发展新机遇。是次合作将涵盖多个范畴。双方将共同探索及开发创新智能信贷方案，结合贸易通的报关数据优势与Fusion Bank的数码贷款能力，为具跨境业务的中小企提供更具针对性的融资选项，推动普及金融的发展。同时，贸易通与Fusion Bank作为香港金融管理局"商业数据通"的合作伙伴，将透过该平台实现数据分享，进一步加强数码整合与客户互动，无缝衔接贸易数据与金融服务，协助中小企更便捷地开展贸易融资。贸易通亦会为中小企提供贸易合规支持。另外，Fusion Bank将成为贸易通T+新一代电子贸易服务平台的策略伙伴，为PayConnect及SignConnect等核心模块提供支持。在PayConnect方面，Fusion Bank将发挥其金融科技优势，提供数码化开户、多币种银行服务等，为中小企注入高效融资动力；在SignConnect方面，双方将推动数码身份认证的应用，提升中小企在数码贸易融资中的可信度与便利性。此外，双方将共同举办工作坊及知识分享活动，涵盖跨境电商、中小企数码转型及金融等主题，推动业界交流与能力提升，助力企业掌握数码贸易与金融新趋势。从左到右：Fusion Bank执行董事兼行政总裁徐源宏先生、贸易通执行董事及行政总裁袁民忠先生 S.B.S.贸易通执行董事及行政总裁袁民忠先生 S.B.S. 表示："我们很高兴与Fusion Bank建立合作关系，结合双方在贸易数据与金融科技的优势，为我们即将正式推出的 T+ 新一代电子贸易服务平台增添动力，推动香港贸易与金融生态圈的融合与创新。"Fusion Bank执行董事兼行政总裁徐源宏先生表示："我们很荣幸可以与贸易通携手加强对中小企的支持。我们将在现有的金融科技基础上进一步加强数据应用，借助贸易通30多年的贸易数据及行业经验，为中小企提供更度身订造的金融服务，协助它们捕捉业务机遇。"是次合作标志着贸易通与Fusion Bank在推动香港中小企数码化及跨境发展方面迈出重要一步，双方将持续深化合作，携手构建更具可信性与创新的贸易金融生态。借定唔借？还得到先好借！有关贸易通电子贸易有限公司贸易通（股份代号：536）于 1988 年成立并于 2005 年上市，是香港高效数码化的先驱者。自 1997 年以来，公司成功为香港数以万计的机构带来电子方案的优势。贸易通于香港开创多项崭新商业科技应用，包括电子数据联通、数码证书、生物认证及仓库自动化。除了提供供应链和身份管理解决方案的专业知识之外，公司亦在企业对香港特区政府的合规文件市场具有领导地位。贸易通拥有超过 50,000 名客户，遍及各行各业，赢得政府、跨国公司和中小企业的信任。凭借与全球超过一百万客户的连系，贸易通协助企业拓展国际业务，开拓更多市场机遇。更多关于贸易通详情，请浏览 https://www.tradelink.com.hk关于Fusion Bank （"富融银行"）Fusion Bank于 2019 年获香港金融管理局发出银行牌照经营数字银行业务，旨在促进本地金融发展，为客户提供便捷、优惠和安全的银行与金融科技服务。Fusion Bank为腾讯控股有限公司控股企业，其他股东包括：中国工商银行 （亚洲）有限公司、香港交易及结算所有限公司、高瓴资本以及香港著名商人郑志刚先生。Fusion Bank总部设于香港，并严格遵守相关的监管规定及指引。更多关于Fusion Bank详情，请浏览 https://www.fusionbank.com/ Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

THE HAGUE, NETHERLANDS, Dec 10, 2025 - (ACN Newswire via SeaPRwire.com) - The Global Anti-Scam Alliance (GASA) is pleased to announce that Nasdaq Verafin has joined GASA as a Foundation Member, strengthening the global effort to combat scams, financial crime, and digital fraud. As fraud tactics continue to evolve across borders and digital channels, cross-sector collaboration has become essential to protecting consumers and building safer financial ecosystems.Nasdaq Verafin's participation marks a meaningful step forward in the shared mission to advance trust, transparency, and resilience across the globe. In addition to joining the global effort, Nasdaq Verafin will join both the Brazil and Mexico chapters of GASA to partner with stakeholders across the financial ecosystem in Latin America, bolstering regional initiatives to combat financial crime."Criminals are innovating at an unprecedented rate, taking advantage of information siloes and the shortcomings of legacy technology to avoid detection. We are at an inflection point in the fight against financial crime, one that requires the entire ecosystem to come together, leveraging the power of collective intelligence to strengthen our defenses and better protect consumers around the globe. We look forward to partnering closely with the Global Anti-Scam Alliance to share innovative solutions, intelligence, and global expertise to the unique challenges financial institutions in Brazil and Mexico face," said Mauriceo Castanheiro, Head of International Payments Fraud at Nasdaq Verafin.Nasdaq Verafin is a global leader in financial crime management technology solutions, trusted by more than 2,700 financial institutions around the globe. The company's innovative approach combines consortium data, AI, and machine learning to deter, detect, and prevent criminal activity. Nasdaq Verafin's consortium approach uncovers hidden risks across the financial system, leveraging data and insights from across 800 million counterparties to improve fraud detection and prevention while reducing false positives."Having Nasdaq Verafin join the Global Anti-Scam Alliance as a Foundation Member is a milestone for our organization and for the global fight against scams. Their deep expertise in leveraging technology to more efficiently and effectively detect criminal activity brings a new level of insight and influence to our mission. With Nasdaq Verafin's partnership, and their representatives joining the boards of our Brazil and Mexico Chapters, we are strengthening our ability to connect global knowledge with local action. Together, we can help shape stronger policies, accelerate industry collaboration, and build the foundations of a scam free future." said Jorij Abraham, Managing Director of GASA."The addition of Nasdaq Verafin as a Foundation Member is not only a milestone for the Brazil Chapter, it is a strong endorsement of the relevance of our market and the seriousness of the work we have been building from day one. We are starting our journey already alongside a globally recognized institution known for excellence, innovation, and a deep commitment to integrity. This partnership strengthens our ability to translate global expertise into local impact and accelerates our mission to raise the standard of collaboration in the fight against scams and financial crime in Brazil." said Renata Salvini, Chapter Director for Brazil."With 76 percent of Mexican adults victimized by scams and 139 billion pesos lost annually, according to the 2025 State of Scams in Mexico Report, 2026 will be devastating. AI democratized productivity but industrialized fraud, this isn't a prediction, it's a countdown. Combating this epidemic requires integrated defenses where early detection triggers coordinated action across digital platforms, telecommunications, finance, and authorities. Nasdaq Verafin's addition to GASA Mexico bridges the gap between technology and coordination. Without systemic collaboration, our economic system remains vulnerable. This strengthens our multistakeholder commitment to essential stability", added Sissi de la Peña, Chapter Director for Mexico.Through this partnership, Nasdaq Verafin executives will join the Chapter Advisory Boards of GASA Mexico and Brazil. As a Foundation Member, Nasdaq Verafin will collaborate with GASA and its members, bringing insights from more than two decades of stopping financial crime to develop innovative new strategies that protect consumers from fraud and scams.To learn more about Nasdaq Verafin's approach to financial crime detection and prevention, visit www.verafin.com.About the Global Anti-Scam Alliance (GASA)The Global Anti-Scam Alliance is a non profit organization whose mission is to protect consumers worldwide from scams. GASA brings together policymakers, law enforcement agencies, consumer authorities, NGOs, the financial sector, telecom operators, internet platforms, service providers, and cybersecurity organizations to share insights, uncover emerging scams, and promote coordinated action against fraud. Learn more at https://www.gasa.org.About Nasdaq VerafinNasdaq Verafin provides Financial Crime Management Technology solutions for Fraud Detection and Management, AML/CFT Compliance and Management, High Risk Customer Management, Sanctions Screening and Management, and Information Sharing. More than 2,700 financial institutions, representing 11 trillion dollars in collective assets, use Nasdaq Verafin to prevent fraud and strengthen AML/CFT efforts. Visit www.verafin.com to learn more.Cautionary Note Regarding Forward-Looking Statements:Information set forth in this release contains forward-looking statements that involve a number of risks and uncertainties. Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Forward-looking statements can be identified by words such as "will", "may" and other words and terms of similar meaning. Such forward-looking statements include, but are not limited to, statements related to future actions and expected results. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These risks and uncertainties are detailed in Nasdaq's filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on Nasdaq's investor relations website at http://ir.nasdaq.com and the SEC's website at www.sec.gov. Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.© 2005 Nasdaq, Inc. The Nasdaq logo and the Nasdaq ‘ribbon' logo are the registered and unregistered trademarks, or service marks, of Nasdaq, Inc. in the U.S. and other countries. All rights reserved. This communication and the content found by following any link herein are being provided to you by Nasdaq, Inc. and/or certain of its subsidiaries (collectively, "Nasdaq"), for informational purposes only. Nasdaq makes no representation or warranty with respect to this communication or such content and expressly disclaims any implied warranty under law. At the time of publication, the information herein was believed to be accurate, however, such information is subject to change without notice. Nothing herein shall constitute a recommendation, solicitation, invitation, inducement, promotion, or offer for the purchase or sale of any investment product, nor shall this material be construed in any way as investment, legal, or tax advice, or as a recommendation, reference, or endorsement by Nasdaq.GASA Media ContactMetje van der MeerMarketing Directormetje.vandermeer@gasa.org+31 6 48456282Nasdaq Contact:Nick EghtessadCorporate Communicationsnick.eghtessad@nasdaq.com+1 929 996-8894SOURCE: Global Anti-Scam Alliance Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

KUALA LUMPUR, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – CBL International Limited (NASDAQ: BANL) (the “Company” or “CBL”), the listing vehicle of the Banle Group (“Banle” or “the Group”) is honored to announce that Dr. Teck Lim Chia, Chairman and Chief Executive Officer of CBL International Limited, has been selected as an Awardee in the Directors of the Year Awards – Listed Companies Executive Directors category, presented by the Hong Kong Institute of Directors (HKIoD).This esteemed accolade follows a comprehensive evaluation by an independent panel of judges comprising senior business leaders, governance experts, and institutional investors. The award recognizes Dr. Chia’s outstanding contributions to corporate governance, exemplary board leadership, and his proven track record in driving sustainable value creation for shareholders and stakeholders.The HKIoD Directors of the Year Awards are among Asia’s most respected honors in corporate governance. Awardees are chosen based on demonstrated excellence in strategic oversight, ethical leadership, transparency, and long-term sustainable performance—all hallmarks of Dr. Chia’s tenure at CBL International. As Chairman and CEO, Dr. Chia has led the Group through a period of transformative growth while embedding governance excellence into the company’s core. Under his stewardship, CBL has strengthened its investor relations framework, enhanced ESG disclosures, deepened stakeholder engagement, and maintained rigorous compliance with international standards throughout its expansion across Asia Pacific, Europe, Central America and Africa.In accepting the award, Dr. Teck Lim Chia said: “I am deeply humbled and grateful to receive this prestigious recognition from the Hong Kong Institute of Directors. This honor belongs not to me alone, but to our entire board, management team, and employees who share a relentless commitment to integrity, innovation, and responsible growth. At CBL, we believe governance is not a box to check — it is the compass that guides every decision. I will continue to lead with purpose, accountability, and vision, always placing the long-term interests of our stakeholders first.”The Board of CBL International expressed its pride in Dr. Chia’s achievement: “Dr. Chia’s leadership has been instrumental in shaping CBL into a globally recognized, governance-forward enterprise. His ability to balance strategic ambition with disciplined oversight exemplifies what modern corporate leadership should be. We congratulate him on this well-deserved honor.”Photo caption: Dr. Teck Lim Chia (right), Chairman and CEO of CBL International Limited, honored at the Directors of the Year Awards – Listed Companies Executive Directors category by the Hong Kong Institute of Directors (HKIoD).Photo caption: The trophy for Directors of the Year Awards – Listed Companies Executive Directors category by the Hong Kong Institute of Directors (HKIoD).About the Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications.For more information about our Company, please visit our website at: https://www.banle-intl.com. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

吉隆坡, 2025年12月11日 - (亚太商讯 via SeaPRwire.com) - 亚太地区领先的船用燃料物流公司万利集团（"万利"或"该集团"）之上市主体CBL International Limited（纳斯达克股票代码：BANL）（以下简称"公司"或"CBL"）宣布，集团主席兼行政总裁谢威廉博士在由香港董事学会（HKIoD）主办的"年度董事大奖"中，荣获"上市公司执行董事"类别大奖。此项殊荣经过由资深商业领袖、公司治理专家及机构投资者组成的独立评审团全面评估后授予。该奖项表彰了谢威廉博士在公司治理方面的卓越贡献、卓越的董事会领导能力，以及其在为股东及持份者创造可持续价值方面的杰出成就。香港董事学会"年度董事大奖"是亚洲最具声望的公司治理荣誉之一。 获奖者基于在策略监督、道德领导、透明度及长期可持续表现方面的卓越表现而获选——这些正是谢威廉博士在CBL International内的核心特质。作为集团主席兼行政总裁，谢博士引领集团经历转型式增长，同时将卓越治理融入公司核心。在他的领导下，CBL加强了投资者关系框架，提升了环境、社会及管治（ESG）披露水平，深化了持份者参与度，并在集团业务拓展至亚太地区、欧洲、中美洲及非洲的过程中，始终保持严格的国际标准合规性。谢威廉博士在领奖时表示："能够获得香港董事学会这一崇高荣誉，我感到谦卑与感激。此项殊荣不仅属于我个人，更属于我们整个董事会、管理团队及全体员工，他们与我一样，对诚信、创新及负责任增长怀有不懈承诺。在CBL，我们深信公司治理绝非简单的合规检查——它是指引每一项决策的指南针。我将继续以目标、问责及远见引领集团发展，始终将持份者的长期利益置于首位。"公司董事会表示："谢威廉博士的领导力对塑造CBL成为全球认可、以治理为先的企业至关重要。他能够在策略雄心与审慎监督之间取得平衡的能力，充分体现了现代企业领导者应有的风范。我们衷心祝贺他获得此项实至名归的荣誉。"图片说明：CBL International Limited 主席兼行政总裁谢威廉博士（右），获颁香港董事学会"年度董事大奖"之"上市公司执行董事"类别殊荣。图片说明：香港董事学会"年度董事大奖"之"上市公司执行董事"奖杯关于万利集团万利集团成立于 2015 年，以CBL International Limited（纳斯达克：BANL）在纳斯达克股票市场上市。我们致力于为客户提供一站式燃油供应服务，被业内称为燃油供应服务商。我们主要通过当地实体供货商为船舶提供燃油加注服务，遍布比利时、中国、香港、印度、日本、韩国、马来西亚、毛里裘斯、巴拿马、菲律宾、新加坡、台湾、泰国、土耳其和越南，共覆盖65个港口。集团积极推动可持续燃料，并已取得ISCC EU和ISCC Plus认证。如欲了解更多信息，请到集团网站https://www.banle-intl.com浏览。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com